BiotechTube

Luspatercept

Pre-clinicalRecruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

β-thalassemia

Conditions

β-thalassemia

Trial Timeline

Feb 26, 2026 → Apr 17, 2031

NCT ID
NCT07215975

About Luspatercept

Luspatercept is a pre-clinical stage product being developed by Bristol Myers Squibb for β-thalassemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07215975. Target conditions include β-thalassemia.

What happened to similar drugs?

1 of 2 similar drugs in β-thalassemia were approved

Approved (1) Terminated (1) Active (1)
✅DeferasiroxNovartisApproved
🔄DeferasiroxNovartisPhase 3

Hype Score Breakdown

Clinical
3
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT07215975Pre-clinicalRecruiting
NCT07073690Pre-clinicalActive
NCT06788691Phase 2Recruiting
NCT07075406Pre-clinicalCompleted
NCT06596642Pre-clinicalActive
NCT06073860Pre-clinicalRecruiting
NCT06045689Phase 3Active
NCT05891249ApprovedActive
NCT05732961Phase 2Recruiting

Competing Products

8 competing products in β-thalassemia

See all competitors
ProductCompanyStageHype Score
luspaterceptMerckPhase 2
35
DeferasiroxNovartisApproved
35
Deferasirox + Deferoxamine (DFO)NovartisPhase 2
27
DeferasiroxNovartisPhase 1
29
DeferasiroxNovartisPhase 3
40
LuspaterceptBristol Myers SquibbPre-clinical
30
PTG-300Protagonist TherapeuticsPhase 2
32
PTG-300Protagonist TherapeuticsPhase 2
32